(S, R, S) -AHPC-C8-NH2
(S, R, S) -AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S, R, S) -AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1[1].
Product Specifications
CAS Number
2341796-79-8
Product Name Alternative
VH032-C8-NH2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
E3 Ligase Ligand-Linker Conjugates
Type
Reference compound
Related Pathways
PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/s-r-s-ahpc-c8-nh2.html
Purity
97.04
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(N(C[C@H](O)C1)[C@@H]1C(NCC2=CC=C(C(SC=N3)=C3C)C=C2)=O)[C@H](C(C)(C)C)NC(CCCCCCCCN)=O
Molecular Formula
C31H47N5O4S
Molecular Weight
585.80
Precautions
H302, H315, H319, H335
References & Citations
[1] Jian Jin, et al. Serine threonine kinase (akt) degradation / disruption compounds and methods of use. Patent WO2019173516A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Von Hippel-Lindau (VHL)
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-CD3e (145-2C11) In Vivo Antibody - Low Endotoxin
HGF / SF (EGH2 4C12.1), CF740 conjugate, 0.1mg/mL
